{"name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","slug":"jiangsu-alphamab-biopharmaceuticals-co-ltd","ticker":"","exchange":"","domain":"jiangsualphamabbiopharmaceuticals.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Concurrent chemotherapy and KN026","genericName":"Concurrent chemotherapy and KN026","slug":"concurrent-chemotherapy-and-kn026","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"},{"name":"Eribulin mesylate injection","genericName":"Eribulin mesylate injection","slug":"eribulin-mesylate-injection","indication":"Metastatic breast cancer","status":"phase_3"},{"name":"JSKN003","genericName":"JSKN003","slug":"jskn003","indication":"Advanced solid tumors (Phase 3 development)","status":"phase_3"},{"name":"JSKN016 injection","genericName":"JSKN016 injection","slug":"jskn016-injection","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"},{"name":"KN046","genericName":"KN046","slug":"kn046","indication":"Advanced or metastatic non-small cell lung cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"JSKN033 Injection","genericName":"JSKN033 Injection","slug":"jskn033-injection","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Concurrent chemotherapy and KN026","genericName":"Concurrent chemotherapy and KN026","slug":"concurrent-chemotherapy-and-kn026","phase":"phase_2","mechanism":"KN026 is a monoclonal antibody targeting PD-L1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"Eribulin mesylate injection","genericName":"Eribulin mesylate injection","slug":"eribulin-mesylate-injection","phase":"phase_3","mechanism":"Eribulin mesylate is a microtubule dynamics inhibitor that binds to tubulin and suppresses microtubule growth, leading to cell cycle arrest and apoptosis in cancer cells.","indications":["Metastatic breast cancer","Liposarcoma","Other solid tumors (in clinical development)"],"catalyst":""},{"name":"JSKN003","genericName":"JSKN003","slug":"jskn003","phase":"phase_3","mechanism":"JSKN003 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.","indications":["Advanced solid tumors (Phase 3 development)"],"catalyst":""},{"name":"JSKN016 injection","genericName":"JSKN016 injection","slug":"jskn016-injection","phase":"phase_2","mechanism":"JSKN016 injection is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"JSKN033 Injection","genericName":"JSKN033 Injection","slug":"jskn033-injection","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KN046","genericName":"KN046","slug":"kn046","phase":"phase_3","mechanism":"KN046 is a bispecific antibody that simultaneously engages PD-L1 on tumor cells and 4-1BB on T cells to enhance anti-tumor immune responses.","indications":["Advanced or metastatic non-small cell lung cancer","Other solid tumors (in clinical development)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxObTN3R1ZmTjJIbjNzQkFDeFBJQ250bnc0MjV5TURWamtOMkNudklJVFE2WU9waW9rdGRkdUhaQWlnNzhLemw1TVdJRnhOcm1FTGowemdtT2R4NzlpdUZZVWFXZndsbUVOaWRLWDNqVURaWVVfNjJiUWVINkkzR3N0bWdOUllXV3ZhTU1wMXRpRXp6MnF2Z2Iwb2szcXNXSVRYWGlyWXE5c1ZrYjNzLWgxZWc0U0U0YU9lTE9fT1Z4WDNpNk15STRmY05ZVExOY3RSdDVNbVJNYmY0SVNTTzNvNjdCWHRPZXlVVVdZV2hNMENzOUdMcU1MUy1YVGkzcHRLT2paTjR6anhyV1p3b0ZaTV9FOU5mamwxeFYyRzY3ZDBscEtu?oc=5","date":"2026-03-17","type":"trial","source":"StreetInsider","summary":"HER2 Positive Breast Cancer Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight - StreetInsider","headline":"HER2 Positive Breast Cancer Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-03-11","type":"pipeline","source":"The Manila Times","summary":"Alphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer - The Manila Times","headline":"Alphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFB2ZGJvWmFFLVVfQk1IZ2txa3l3TnJZc0cxOFhhVGwzQWNTNWR2cGFwX0wwNmhNenA1cjFXV012eWtWbDBBUVFpdEdwNVMyQ3ZheUYza1dGUHFfdzlId1pER3dHaHAxY3ZEdktTcHBB?oc=5","date":"2024-10-30","type":"deal","source":"Law.asia","summary":"CSPC signs an exclusive license agreement with Jiangsu Alphamab for the development and commercialization of JSKN003 in mainland China - Law.asia","headline":"CSPC signs an exclusive license agreement with Jiangsu Alphamab for the development and commercialization of JSKN003 in ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxNd2ZiWkdHMXRkUUZuWWtCbUx6OFRIRHFGOHZaWTF5ZjAteExrVF9lSFQ0dnFkX0czWXg2Nk4wVGhud0lCd25tWEtNZm5HSkllam42VmdReFBrZjdhNlNFQ3hhX3J4ZS15ZjRrcHcxR1hTNnYwcWcxeEhSZFZudzFnaVBNS25nOG55RUhfM3ZERWozOGxFMkZTT1c4bVkwdlZMb3pLNEZXQmM3SXRhQVdCQ011VGJWNWpRQkhmMXZQRVZpR2NIVFFSNmE2Y1cwel9IXzBxS3JaNnV0YjFLZmpHdmVpaFd6dGtBUnBMYm5NcERINzZyVDgzLXdvT1lhVWxzdW53VkxXYlpTR2cxNk1oYWI5TThtT0FTYy04c2syUEhLcDBtUTB6V3RCRm9JdG9saVNWT1RZN0xNdzVxR28yUWRmWXpkWXF2?oc=5","date":"2024-01-25","type":"deal","source":"PR Newswire","summary":"Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World - PR Newswire","headline":"Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (En","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-01-25","type":"pipeline","source":"The Economic Times","summary":"Glenmark inks licensing pact with Jiangsu Alphamab, 3D Medicines for cancer drug - The Economic Times","headline":"Glenmark inks licensing pact with Jiangsu Alphamab, 3D Medicines for cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPYXFwZ3BwV3JmVkVSakFUUnpaQVhFcFdseXlEY3RIUUdTMFVlaC1HR0RuQkhYSDYzQW1UcGU3R2pHOGZOUHhKUjdtQ3FPQzcwY1VVLWJPOUFjZUdkS3FVSExlRUJmdlNaZHJTNDB1bktlMHVwQ04xdnoxQTI5WWg2MnJ1UmZ5NGUxMnVqbS13dzdKdUZ5RlZNS2xoWVVRWmpPRTBpbUZLMF9SVVFXYWRJeXlZYkRqd2NBXzV0OE9wU1p4YXM1enVtbl9zRElqQjhpX0swUldGcy0xTlRXbU5lbG9HeXhreEg3elllYW1Hc2RSY3pTU3ZWWEVIYWE1NV90Uld3X05vbXQ?oc=5","date":"2022-07-26","type":"pipeline","source":"PR Newswire","summary":"New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsight - PR Newswire","headline":"New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsi","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_2":3,"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}